Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
AIM: N-3 fatty acids, especially eicosapentaenoic acid (EPA), may possess anticachectic properties. This trial compared a protein and energy dense supplement enriched with n-3 fatty acids and antioxidants (experimental: E) with an isocaloric isonitrogenous control supplement (C) for their effects on weight, lean body mass (LBM), dietary intake, and quality of life in cachectic patients with advanced pancreatic cancer. METHODS: A total of 200 patients (95 E; 105 C) were randomised to consume two cans/day of the E or C supplement (480 ml, 620 kcal, 32 g protein +/- 2.2 g EPA) for eight weeks in a multicentre, randomised, double blind trial. RESULTS: At enrolment, patients' mean rate of weight loss was 3.3 kg/month. Intake of the supplements (E or C) was below the recommended dose (2 cans/day) and averaged 1.4 cans/day. Over eight weeks, patients in both groups stopped losing weight (delta weight E: -0.25 kg/month versus C: -0.37 kg/month; p = 0.74) and LBM (Delta LBM E: +0.27 kg/month versus C: +0.12 kg/month; p = 0.88) to an equal degree (change from baseline E and C, p<0.001). In view of evident non-compliance in both E and C groups, correlation analyses were undertaken to examine for potential dose-response relationships. E patients demonstrated significant correlations between their supplement intake and weight gain (r = 0.50, p<0.001) and increase in LBM (r = 0.33, p = 0.036). Such correlations were not statistically significant in C patients. The relationship of supplement intake with change in LBM was significantly different between E and C patients (p = 0.043). Increased plasma EPA levels in the E group were associated with weight and LBM gain (r = 0.50, p<0.001; r = 0.51, p = 0.001). Weight gain was associated with improved quality of life (p<0.01) only in the E group. CONCLUSION: Intention to treat group comparisons indicated that at the mean dose taken, enrichment with n-3 fatty acids did not provide a therapeutic advantage and that both supplements were equally effective in arresting weight loss. Post hoc dose-response analysis suggests that if taken in sufficient quantity, only the n-3 fatty acid enriched energy and protein dense supplement results in net gain of weight, lean tissue, and improved quality of life. Further trials are required to examine the potential role of n-3 enriched supplements in the treatment of cancer cachexia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Principles of nutritional assessment
(1990) · Choice Reviews Online · doi:10.5860/choice.27-6362 · Cited by 2,765
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200501 · Cited by 1,910
Causes of death in cancer patients
Inagaki, J., Rodriguez, V., & Bodey, G. P. (1974) · Cancer · doi:10.1002/1097-0142(197402)33:2<568::aid-cncr2820330236>3.0.co;2-2 · Cited by 601
Barber, M. D., Ross, J. A., Voss, A. C., Tisdale, M. J., & Fearon, K. C. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690654 · Cited by 459
Self-citationBramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., Buckels, J. A. C., & for the Marimastat Pancreatic Cancer Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3447 · Cited by 438
Characterization of a cancer cachectic factor
Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K., & Tisdale, M. (1996) · Nature · doi:10.1038/379739a0 · Cited by 437
Self-citationRelationship between total body water and surface area in normal and obese subjects
Hume, R., & Weyers, E. (1971) · Journal of Clinical Pathology · doi:10.1136/jcp.24.3.234 · Cited by 377
Gogos, C. A., Ginopoulos, P., Salsa, B., Apostolidou, E., Zoumbos, N. C., & Kalfarentzos, F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980115)82:2<403::aid-cncr21>3.0.co;2-1 · Cited by 311
Cited by
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Self-citationBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Self-citationTisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., Mackey, J. R., Koski, S., Pituskin, E., & Sawyer, M. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2242 · Cited by 1,104
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Self-citationESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., van Bokhorst-de van der Schueren, M. A. E., von Meyenfeldt, M., Zürcher, G., Fietkau, R., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.020 · Cited by 930
Self-citationDiagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R. T., Chasen, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1894 · Cited by 798
Self-citationCachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
Fearon, K. C., Voss, A. C., & Hustead, D. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1345 · Cited by 779
Self-citationThomas, D. R. (2007) · Clinical Nutrition · doi:10.1016/j.clnu.2007.03.008 · Cited by 521
Stark, K. D., Van Elswyk, M. E., Higgins, M. R., Weatherford, C. A., & Salem, N. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.05.001 · Cited by 519
August, D. A., Huhmann, M. B., & the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors (2009) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607109341804 · Cited by 516
Isenring, E. A., Capra, S., & Bauer, J. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601962 · Cited by 494
Moses, A. W. G., Slater, C., Preston, T., Barber, M. D., & Fearon, K. C. H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601620 · Cited by 452
Self-citationCancer cachexia: Developing multimodal therapy for a multidimensional problem
Fearon, K. C. H. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.033 · Cited by 444
Self-citationCancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413
“The secondary end point, weight, requires cautious interpretation because, in contrast to other trials lasting 8 to 12 weeks or longer, this trial was only 6 weeks long; however, in some of those trials, weight gain was observed after 4 weeks.(47,48) The degree of weight loss in our patients was lower (11.”
ResultNutrition interventions to treat low muscle mass in cancer
Prado, C. M., Purcell, S. A., & Laviano, A. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12525 · Cited by 392
Multi-targeted therapy of cancer by omega-3 fatty acids
Berquin, I. M., Edwards, I. J., & Chen, Y. Q. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.044 · Cited by 364
A systematic review of compliance to oral nutritional supplements
Hubbard, G. P., Elia, M., Holdoway, A., & Stratton, R. J. (2012) · Clinical Nutrition · doi:10.1016/j.clnu.2011.11.020 · Cited by 343
Systemic inflammation, cachexia and prognosis in patients with cancer
Deans, C., & Wigmore, S. J. (2005) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000165004.93707.88 · Cited by 331
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T., & Goggin, P. M. (2005) · Gut · doi:10.1136/gut.2004.047563 · Cited by 322
Therapy Insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself
Laviano, A., Meguid, M. M., Inui, A., Muscaritoli, M., & Rossi-Fanelli, F. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0112 · Cited by 322
Fatigue in palliative care patients — an EAPC approach
Radbruch, L., Strasser, F., Elsner, F., Gonçalves, J. F., Løge, J., Kaasa, S., Nauck, F., Stone, P., & the Research Steering Committee of the European Association for Palliative Care (EAPC) (2008) · Palliative Medicine · doi:10.1177/0269216307085183 · Cited by 317
Solheim, T. S., Laird, B. J. A., Balstad, T. R., Stene, G. B., Bye, A., Johns, N., Pettersen, C. H., Fallon, M., Fayers, P., Fearon, K., et al. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12201 · Cited by 311
Self-citationOmega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer
Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2012) · Gut · doi:10.1136/gut.2010.233718 · Cited by 305
Lee, C., & Longo, V. D. (2011) · Oncogene · doi:10.1038/onc.2011.91 · Cited by 303
Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., Gagnon, B., Novotny, P. J., Mailliard, J. A., Bushey, T. I. L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.024 · Cited by 296
Murphy, R. A., Mourtzakis, M., Chu, Q. S. C., Baracos, V. E., Reiman, T., & Mazurak, V. C. (2011) · Cancer · doi:10.1002/cncr.25709 · Cited by 288
Deutz, N. E. P., Pereira, S. L., Hays, N. P., Oliver, J. S., Edens, N. K., Evans, C. M., & Wolfe, R. R. (2013) · Clinical Nutrition · doi:10.1016/j.clnu.2013.02.011 · Cited by 287
Nutritional intervention and quality of life in adult oncology patients
Marín Caro, M. M., Laviano, A., & Pichard, C. (2007) · Clinical Nutrition · doi:10.1016/j.clnu.2007.01.005 · Cited by 286
Fearon, K. C. H., Barber, M. D., Moses, A. G., Ahmedzai, S. H., Taylor, G. S., Tisdale, M. J., & Murray, G. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5724 · Cited by 281
Self-citationCancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273
Cancer cachexia—pathophysiology and management
Suzuki, H., Asakawa, A., Amitani, H., Nakamura, N., & Inui, A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0787-0 · Cited by 268
Nutritional screening and early treatment of malnutrition in cancer patients
Santarpia, L., Contaldo, F., & Pasanisi, F. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0022-x · Cited by 267
Dewey, A., Baughan, C., Dean, T. P., Higgins, B., & Johnson, I. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004597.pub2 · Cited by 257
Hutton, J. L., Baracos, V. E., & Wismer, W. V. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.07.017 · Cited by 238
Therapeutic potential of n-3 polyunsaturated fatty acids in disease
Fetterman, J. W., & Zdanowicz, M. M. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080411 · Cited by 236
Regulation of muscle protein synthesis and the effects of catabolic states
Gordon, B. S., Kelleher, A. R., & Kimball, S. R. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.039 · Cited by 208
“, 2007b), and dietary protein supplementation to cancer patients can maintain bodyweight (Eley et al., 2007a; Eley et al., 2007b; Fearon et al., 2003; Tisdale, 2009).”
BackgroundDavidson, W., Ash, S., Capra, S., & Bauer, J. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2003.07.001 · Cited by 193
Oncology Evidence-Based Nutrition Practice Guideline for Adults
Thompson, K. L., Elliott, L., Fuchs-Tarlovsky, V., Levin, R. M., Voss, A. C., & Piemonte, T. (2017) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2016.05.010 · Cited by 184
Solheim, T. S., Laird, B. J. A., Balstad, T. R., Bye, A., Stene, G., Baracos, V., Strasser, F., Griffiths, G., Maddocks, M., Fallon, M., et al. (2018) · BMJ Supportive & Palliative Care · doi:10.1136/bmjspcare-2017-001440 · Cited by 178
Self-citationCancer-Associated Cachexia and Underlying Biological Mechanisms
Baracos, V. E. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111151 · Cited by 177
van der Meij, B. S., Langius, J. A. E., Spreeuwenberg, M. D., Slootmaker, S. M., Paul, M. A., Smit, E. F., & van Leeuwen, P. A. M. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2011.214 · Cited by 171
“16 Up to now, a few randomised controlled trials showed promising effects of n-3 polyunsaturated FAs on quality of life and functional status in cancer patients receiving palliative care, without assessing physical activity”
BackgroundClinical implications of sarcopenic obesity in cancer
Carneiro, I. P., Mazurak, V. C., & Prado, C. M. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0546-5 · Cited by 162
Nutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114
Bounoure, L., Gomes, F., Stanga, Z., Keller, U., Meier, R., Ballmer, P., Fehr, R., Mueller, B., Genton, L., Bertrand, P. C., et al. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.019 · Cited by 103
Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.
Shadfar, S., Couch, M. E., McKinney, K. A., Weinstein, L. J., Yin, X., Rodríguez, J. E., Guttridge, D. C., & Willis, M. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.563032 · Cited by 98
“These include high-dose progestins ( 59 ), eicosapentaenoic acid (EPA) ( 60 ), β-hydroxy-β-methylbutyrate (HMB) ( 61 ), thalidomide ( 62 ), and NSAIDs ( 63 ).”
Liu, Y., Chen, F., Odle, J., Lin, X., Zhu, H., Shi, H., Hou, Y., & Yin, J. (2013) · The Journal of Nutrition · doi:10.3945/jn.113.176255 · Cited by 74
Wang, H., Li, T.-L., Hsia, S., Su, I.-L., Chan, Y.-L., & Wu, C.-J. (2015) · Oncotarget · doi:10.18632/oncotarget.3483 · Cited by 39
Ogasawara, T., Marui, S., Miura, E., Sugiura, M., Matsuyama, W., Aoshima, Y., Kasamatsu, N., Ogiku, M., & Ikematsu, Y. (2018) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2018.09.076 · Cited by 32
Metadata
- Authors
- Fearon, K. C. H.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2003-10-01
- Volume
- 52
- Issue
- 10
- Pages
- 1479-1486
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2109956558
- Cited by
- 603
- References
- 27
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.